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Hyperhomocysteinemia predicts cardiovascular outcomes in determining the high mortality of patients with end-stage
hemodialysis patients. renal disease (ESRD) is complex because of the high
Background. We prospectively tested the prediction power prevalence of multiple risk factors [2]. Hyperhomocys-
of homocysteinemia for all-cause and cardiovascular outcomes
teinemia was suspected as a cardiovascular risk factorin a cohort of 175 hemodialysis patients followed for 29  12
in chronic renal failure in the eighties [3], and the prob-months.
Methods. Survival analysis was performed by the Cox’s pro- lem was examined in several cross-sectional and mecha-
portional hazard model and data were expressed as hazard nistic studies [4–18]. In this regard, the observations that
ratio and 95% confidence interval (CI). plasma homocysteine is independently related to aortic
Results. During the follow-up period 51 patients died, 31 of stiffness [19] and left ventricular hypertrophy [20] arethem (61%) of cardiovascular causes and 16 patients developed
of particular interest. However, apart from the seminalnon-fatal atherothrombotic complications. Plasma total homo-
studies by Bostom et al [21] and Moustapha et al [22]cysteine was an independent predictor of cardiovascular mor-
tality (P  0.01). Combined analysis of fatal and non-fatal in a total of 240 patients, there is a lack of prospective
atherothrombotic events showed that homocysteine was a investigations linking hyperhomocysteinemia to cardio-
strong and independent predictor of these outcomes because vascular mortality in hemodialysis patients. The issue is
the risk of these events was 8.2 times higher (95% CI 1.9 to
relevant mainly because a recent study suggested that32.2) in patients in the third homocysteine tertile than in those
reduced plasma homocysteine concentration, rather thanin the first tertile (P  0.005).
hyperhomocysteinemia, predicts survival in these pa-Conclusions. There is a clear association between hyperho-
mocysteinemia and incident cardiovascular mortality and ath- tients [23].
erothrombotic events in hemodialysis patients. Intervention Our current study prospectively tested the association
studies are needed to determine whether the accumulation of between plasma total homocysteine and all-cause and car-this substance has a causal role in the pathogenesis of cardiovas-
diovascular outcomes in a large cohort of hemodialysiscular damage in patients undergoing hemodialysis.
patients. Since cardiovascular risk is inherently multifac-
torial, the role of hyperhomocysteinemia was analyzed
in multivariable models encompassing traditional andCardiovascular disease accounts for approximately 50%
nontraditional risk factors and factors peculiar to ESRD.of mortality among patients on chronic dialysis and a
similarly high mortality rate has been observed in the
United States and in Europe [1]. The appreciation of METHODS
the relative role of traditional (that is, Framingham risk Protocol
factor) and nontraditional cardiovascular risk factors in
The protocol conformed to the ethical guidelines of
our Institutions and informed consent was obtained from
Key words: dialysis, cardiovascular risk, homocysteine, arteriovenous each participant. All studies were performed during a
disease, thrombosis, blood pressure, mortality study. non-dialysis day, between 8 a.m. and 10 a.m.
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regular dialysis treatment (RDT) for at least six months fibrinogen, total homocysteine, B6, B12, folate and hemo-
and without clinical evidence of overt cardiovascular con- globin was obtained from all patients during a mid week
gestion [24] were eligible for the study. These patients non-dialysis day. Plasma total homocysteine was deter-
represented about the 70% of the entire hemodialysis mined by a high-pressure liquid chromatography (HPLC)
population of four dialysis units. The remaining patients method based on a derivative of SBD-F (ammonium-7-
were excluded from the study because they were taking fluorobenzo-2-oxa-1,3-diazole-4-sulfonate) fluorescence
folic acid, vitamin B6 and B12 supplements (11%), or be- [25]. CRP was measured by using a commercially avail-
cause of frank cardiovascular congestion or overt in- able kit (immunoturbidimetric method, lower limit of de-
fections (9%), or because they were hospitalized for tection 3.5 mg/L; Behring, Scoppito, L’Aquila, Italy).
inter-current illnesses (10%). The prevalence of diabetes Vitamin B6 was measured by a radioenzymatic assay for
mellitus in this cohort was 16% (that is, 28 out of 175 direct measurement of plasma pyridoxal 5-phosphate
patients). [26] and plasma folate and vitamin B12 by commercially
All patients were virtually anuric (24-hour urine vol- available competitive immunoassays (direct chemilumi-
ume200 mL/day) and were being treated thrice weekly nescence; Chiron Diagnostic, San Francisco, CA, USA).
with standard bicarbonate hemodialysis (Na 138 mmol/L,
HCO3 35 mmol/L, K 1.5 mmol/L, Ca 1.25 mmol/L, Mg Blood pressure measurements
0.75 mmol/L) or with high-flux hemodialysis either with Blood pressure (BP) was measured before dialysis.
cuprophan or semi-synthetic membranes (dialysis filter The average value of all recordings (12 measurements,
surface area 1.1 to 1.7 m2). Dry weight was targeted in that is, 3 measurements/week) taken during the month
each case to achieve a normotensive edema-free state. preceding the study was considered as a representative
Sixty-one patients were on anti-hypertensive treatment of the BP of each patient [27].
[46 on mono-therapy with angiotensin-converting en-
zyme (ACE) inhibitors, angiotensin II type 1 (AT-1) Statistical analysis
receptor antagonists, calcium channel blockers, alpha- Data are reported as mean  SD or as median and
and beta-blockers, and 15 were on double therapy with inter-quartile range. Comparisons between groups were
various combinations of these drugs]. Sixty-five patients made by the t test or by the Mann-Whitney test, as appro-
were habitual smokers (20  15 cigarettes/day). priate. Independent correlates of plasma homocysteine
were identified by univariate and multivariate linear re-Follow-up study
gression analysis. Variables that had an independent re-After the initial assessment patients were followed up
lationship with plasma homocysteine were ordered ac-for 29  12 months. During the follow-up period fatal
cording to their standardized effect, defined as regressionand non-fatal cardiovascular events [electrocardiogram
coefficient/standard error of the regression ().(ECG)-documented anginal episodes, myocardial infarc-
The independent prediction power of plasma totaltion, heart failure, arrhythmia, transient ischemic attach,
homocysteine for all-cause and cardiovascular outcomesstroke, and major arterial and venous thrombotic epi-
was tested in Cox’s proportional hazards models ad-sodes (except arteriovenous fistula thrombosis)] were ac-
justed for a series of traditional risk factors [age, sex,curately recorded. Myocardial infarction was confirmed
diabetes, smoking, body mass index (BMI), systolic pres-by serial ECG evidence of a Q-wave or non-Q–wave
sure and cholesterol], for emerging risk factors (CRPmyocardial infarction and appropriate creatine phospho-
and fibrinogen) and factors peculiar to ESRD [durationkinase MB fraction elevations. Thrombotic stroke was
of regular dialysis treatment (RDT), hemoglobin, albu-confirmed by computerized tomographic imaging evi-
min and calcium*phosphate product]. Hazard ratiosdence of cerebral infarction and/or neurological exami-
(HR) and their 95% confidence intervals (CI) were cal-nation findings consistent with new-onset focal neurolog-
culated with the use of the estimated regression coeffi-ical deficits lasting 24 hours. Each death was reviewed
cients and their standard errors in the Cox’s regressionand assigned an underlying cause by a panel of five physi-
analysis. All calculations were made using a standardcians who were blinded to the potential independent
statistical package (SPSS for Windows Version 9.0.1,predictor variables. As a part of the review process, all
available medical information about each death was col- 11 Mar 1999; SPSS, Chicago, IL, USA).
lected. This information always included the study and
hospitalization records. In the case of an out-of-hospital
RESULTSdeath, family members were interviewed by telephone
The demographic, anthropometric, clinical and bio-to better ascertain the circumstances surrounding death.
chemical parameters of patients are given in Table 1. In
Laboratory measurements the entire group, plasma total homocysteine (median
28.9 mol/L, interquartile range 20.5 to 46.7 mol/L)A fasting blood sample for serum lipids, albumin, cal-
cium and phosphate, C-reactive protein (CRP), plasma was above the upper limit of the normal range (cutoff
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Table 2. Fatal cardiovascular events and causes of deathTable 1. Demographic, somatometric, clinical and biochemical
characteristics of the study population in the study cohort
Demographic and somatometric data Variable N
Age years 59.515.1
Fatal cardiovascular eventsDuration of RDT months 37.0 (18.0–99)
Myocardial infarction 9Males/females 98/77
Thrombotic stroke 3BMI kg/m2 24.74.4
Hemorragic stroke 3Cardiovascular risk factors
Heart failure 6Systolic pressure mm Hg 141.124.7
Sudden death 3Diastolic pressure mm Hg 77.213.1
Mesenteric infarction 3Diabetics 16%
Arrhythmia 2Smokers 37%
Pulmonary embolism 2Hypercholesterolemia 52%
Other causes of deathOn treatment with erythropoietin 52%
Sepsis/infection 5Biochemical data
Cachexia 4Plasma homocysteine lmol/L 28.9 (20.5–46.7)
Neoplasia 3Plasma B6 nmol/L 15.7 (7.3–23.3) Hyperkalemia 3Plasma B12 pmol/L 434.5 (297.8–984.6) Gastrointestinal hemorrage 2Plasma folate nmol/L 15.4 (10.3–21.1)
Respiratory failure 1Serum total cholesterol mmol/L 5.2 (4.3–6.0)
Diabetes, hyperosmolar coma 1Serum triglycerides mmol/L 1.7 (1.3–2.3)
Treatment withdrawal 1Serum calcium mmol/L 2.270.25
Serum phosphate mmol/L 1.940.39 Total 51
Serum CRP mg/L 5.4 (3.4–16.0)
Plasma fibrinogen mg/dL 342.0 (243.0–465.0)
Serum albumin g/dL 4.20.4
Hemoglobin g/dL 10.81.8
Kt/V 1.200.26 femoral or iliac artery thrombosis in 5, thrombotic stroke
Data are mean  SD, median (inter-quartile range), or percent frequency as in 5 and transient ischemic attack in 1). In a COX regres-
appropriate. Abbreviations are: RDT, regular dialysis treatment; CRP, C-reac-
sion analysis all-cause mortality was explained only bytive protein; Kt/V, fractional urea clearance.
age (HR, 1.06, 95% CI 1.02 to 1.08, P  0.0009) and
previous cardiovascular events (HR, 2.53, 95% CI 1.20 to
5.36, P 0.01). In this model plasma total homocysteine
15 mol/L) in the majority of hemodialysis patients failed to independently predict survival (P  0.15). On
(155 of 175, 89%). the other hand, plasma homocysteine turned out to be
an independent predictor of cardiovascular mortality,
Univariate and multivariate correlates of plasma and the prediction power of plasma homocysteine for
total homocysteine cardiovascular outcomes was also true when the analysis
The univariate analysis showed that plasma total was confined to atherothrombotic events (Table 3) such
homocysteine was inversely related to plasma folate (r as myocardial infarction, thrombotic stroke, mesenteric
	0.30, P  0.0001) and plasma B12 (r  	0.21, P  infarction and pulmonary embolism (these events were
0.02), and directly related to serum albumin (r  0.17, given in detail in Table 2). In this analysis a 10 mol/L
P  0.03) and male sex (plasma total homocysteine in increase in plasma homocysteine was associated with a
males was 32.2 mol/L, interquartile range 22.1 to 35% increase in the incident risk of fatal atherothrom-
53.8 mol/L, and in females was 26.2 mol/L, 19.2 to botic events. Combined analysis of fatal and non-fatal
41.9 mol/L; P  0.03). In multivariate analysis plasma atherothrombotic events confirmed that homocysteine
folate (  	0.28, P 0.001), serum albumin (  0.28, was an independent predictor of these outcomes (Ta-
P  0.009) and male sex (  0.18, P  0.05) were ble 4). When patients were divided into three tertiles
the only significant correlates of plasma homocysteine according to plasma homocysteine concentration, the
(multiple R 0.48, P 0.0001) while plasma B6, plasma hazard ratio for fatal and non-fatal atherothrombotic
B12, serum cholesterol, serum CRP, Kt/V, age, duration events was progressively higher from the first tertile on-
of RDT, smoking, diabetes, BMI, systolic pressure, and wards, and the hazard ratio of patients with plasma
previous cardiovascular events were unrelated to plasma homocysteine in the third tertile was 8.2 times (95% CI
homocysteine. 1.9 to 32.2) higher than in those in the first tertile (P 
0.005; Fig. 1).
Plasma total homocysteine, all-cause mortality and
cardiovascular outcomes
DISCUSSIONDuring the follow-up period 51 patients died, 31 of
them (61%) of cardiovascular causes (Table 2), and 16 In a large cohort of patients with ESRD total plasma
homocysteine predicted fatal cardiovascular events andpatients developed non-fatal atherothrombotic compli-
cations (myocardial infarction in 2, angina in 3, retinal, established that the link between this risk factor and
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Table 3. COX proportional hazard model for cardiovascular mortality and for cardiovascular mortality due to atherothrombotic events
Units of increase Hazard ratio 95% CI P
Cardiovascular events
Significant predictors
Age 1 year 1.06 1.01–1.10 0.01
Homocysteine 10 mol/L 1.20 1.04–1.38 0.01
Fibrinogen 10 mg/dL 1.03 1.00–1.05 0.03
Previous CV events Yes/no 2.96 1.12–7.81 0.03
Male sex 2.79 1.07–7.32 0.04
Non-significant predictors
Cholesterol 1 mmol/L 1.25 0.95–1.66 0.11
Albumin 1 g/dL 0.42 0.14–1.29 0.13
Systolic pressure 1 mm Hg 1.01 0.99–1.03 0.30
Diabetes 1.78 0.59–5.36 0.31
BMI 1 kg/m2 1.05 0.95–1.15 0.38
Duration of RDT 1 month 1.00 0.99–1.01 0.60
Smoking 1 packet of cigarettes/month 1.00 0.99–1.02 0.69
Calcium 
 phosphate 1 mmol2/L2 0.91 1.00–1.01 0.71
Hemoglobin 1 g/dL 0.96 0.75–1.23 0.76
CRP 1 mg/L 1.00 0.98–1.02 0.80
Atherothrombotic events
Significant predictors
Age 1 year 1.16 1.05–1.29 0.003
Male sex 15.0 2.19–103.4 0.006
Homocysteine 10 mol/L 1.35 1.05–1.73 0.02
Duration of RDT 1 month 1.01 1.00–1.03 0.03
Hemoglobin 1 g/dL 0.61 0.37–1.00 0.05
Non-significant predictors
Smoking 1 packet of cigarettes/month 0.96 0.91–1.01 0.14
Albumin 1 g/dL 4.96 0.54–45.9 0.16
Cholesterol 1 mmol/L 1.41 0.85–2.33 0.18
BMI 1 kg/m2 1.08 0.94–1.25 0.27
Previous CV events 3.33 0.38–29.38 0.28
Systolic pressure 1 mm Hg 1.02 0.98–1.05 0.31
Diabetes 2.31 0.39–13.76 0.36
Fibrinogen 10 mg/dL 1.01 0.96–1.06 0.65
CRP 1 mg/L 1.00 0.98–1.02 0.72
Calcium 
 phosphate 1 mmol2/L2 1.03 0.49–2.17 0.94
Data are expressed as hazard ratios, 95% CI (confidence interval) and P values. In the analysis of fatal atherothrombotic episodes deaths due to myocardial
infarction, thrombotic stroke, mesenteric infarction and pulmonary embolism were included (see also Table 2).
Table 4. COX proportional hazard model for fatal and non-fatal atherothrombotic events
Units of increase Hazard ratio 95% CI P
Significant predictors
Age 1 year 1.06 1.02–1.11 0.004
Homocysteine 10 mol/L 1.18 1.05–1.33 0.005
Non-significant predictors
Systolic pressure 1 mm Hg 1.02 0.99–1.03 0.07
Duration of RDT 1 month 1.01 0.99–1.01 0.07
Diabetes 1.92 0.68–5.43 0.22
BMI 1 kg/m2 1.05 0.97–1.13 0.23
Fibrinogen 10 mg/dL 1.01 0.99–1.04 0.32
Male sex 1.58 0.59–4.21 0.36
Cholesterol 1 mmol/L 0.89 0.68–1.18 0.42
Albumin 1 g/dL 1.59 0.42–5.95 0.49
Smoking 1 packet of cigarettes/month 1.01 0.98–1.03 0.64
Previous CV events Yes/no 1.24 0.40–3.82 0.71
Calcium 
 phosphate 1 mmol2/L2 1.09 0.69–1.73 0.71
Hemoglobin 1 g/dL 0.97 0.75–1.25 0.81
CRP 1 mg/L 1.00 0.98–1.02 0.99
Data are expressed as hazard ratios, 95% CI (confidence interval) and P values.
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second study, homocysteine was by 59% higher in dial-
ysis patients who had fatal and non-fatal cardiovascular
events, and the high cardiovascular risk conferred by
this hyperhomocysteinemia was largely independent of
traditional risk factors and unrelated to all-cause mortal-
ity [22]. In another study in hemodialysis patients homo-
cysteine was associated with all-cause mortality [33]. In
the current study, which was based on the largest hemo-
dialysis cohort studied to date the trend towards total
homocysteine predicting total mortality failed to attain
statistical significance. Notably, in our study the risk of
fatal cardiovascular complications was highly significant
and coincided numerically (20% risk increase for each
10 mol/L increase in plasma total homocysteine; Table
3) with the estimate made in the study by Moustapha et
al [22]. Although the biological mechanism(s) wherebyFig. 1. Cox proportional hazard survival curves for fatal and non fatal
homocysteine may cause damage to organ systems inatherothrombotic events. Patients were divided into three tertiles ac-
cording to their plasma homocysteine concentration: I tertile 22.9 humans has not been fully elucidated, it seems likely that
mol/L; II tertile  22 mol/L; III tertile  37.8 mol/L. Data were
this substance triggers cardiovascular events by causingadjusted for the other independent predictors of fatal and non-fatal
atherothrombotic cardiovascular events (refer to Table 4). oxidative injury to the endothelium and by altering the
coagulation properties of the blood. In this regard, the
strong link between homocysteine and atherothrombotic
events found in our study seems relevant because it hascardiovascular outcomes was largely independent of tra-
a plausible biological basis. Homocysteine predicted car-ditional [21, 22] and non-traditional risk factors such as
diovascular events in a study in transplant patients [34]serum CRP [28–30] and of risk factors peculiar to chronic
but was unrelated to all-cause mortality and graft survivalrenal failure like anemia [31], hypoalbuminemia, hyper-
in another recent study [35]. Our study is the first to testphosphatemia and high calcium-phosphate product [32].
the prediction power of total homocysteine by adoptingHyperhomocysteinemia is found very frequently in
dialysis patients [4–8, 13, 15, 21–23]. In the present study, a statistical approach taking into account other emerging
multivariate analysis based on the main clinical and bio- risk factors (namely CRP) and well-established risk fac-
chemical indicators of the severity of uremia and on the tors peculiar to the uremic state, like anemia [31] and
vitamins that regulate the metabolism of this amino acid hyperphosphatemia [32]. The fact that the relationship
confirmed that serum folate is an independent correlate between hyperhomocysteinemia and cardiovascular
of circulating homocysteine, which is in keeping with pre- mortality and atherothrombotic events is independent
vious observations [8, 1, 15]. Serum albumin is the main of these factors makes the epidemiological association
carrier of circulating homocysteine, and a univariate rela- between this substance and cardiovascular complications
tionship between homocysteine and serum albumin was in the dialysis population even more compelling. Our ob-
noted in a recent study in hemodialysis patients [23]. servation also may help us better understand two recent
Our multivariate analysis confirms that serum albumin is studies reporting a paradoxical link between hyperhomo-
an independent predictor of plasma total homocysteine. cysteinemia and survival in hemodialysis patients [18, 23].
The direct link between homocysteine and albumin ap-
The first was a small-scale study with a short follow-up pe-
pears particularly important, because hypoalbuminemia
riod and did not contemplate cardiovascular events andper se is a predictor of adverse cardiovascular outcomes
death as primary end-points [18], while no statistical ad-and may therefore confound the effect of homocysteine
justment for potential confounders and for traditionalon these outcomes. Such a relationship highlights the com-
and non-traditional risk factors was performed in theplexity and inherent weakness of cross sectional studies
second study [23].aimed at establishing a link between cardiovascular risk
In conclusion, there is a clear association between hyper-and the plasma concentration of this substance.
homocysteinemia and cardiovascular outcomes in dial-The issue as to whether hyperhomocysteinemia pre-
ysis patients. Homocysteine is, at least partially, a modi-dicts cardiovascular outcomes in hemodialysis patients
fiable risk factor [36]. Intervention studies are neededwas examined only in two studies. In the first study the
to determine whether the accumulation of this substancecardiovascular risk was 3.6 times higher in patients with
has a causal role in the pathogenesis of cardiovascularplasma homocysteine greater than 27 mol/L than in
those displaying levels below this threshold [21]. In the damage in hemodialysis patients.
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